Fidim
Also known as Fidim S.r.l., FIDIM
Investment vehicle and family office of the Rovati family (ex-Rottapharm); stakes in biotech, real estate, hospitality and private equity.
USEFUL FOR Co-investors
Investment vehicle / family office of the Rovati family (founders of Rottapharm). Not Fidimpresa or other confidi with similar names.
Family & background
- FAMILY
- Rovati
- WEALTH ORIGIN
- Pharmaceuticals (Rottapharm, sold to Meda in 2014)
- HEADQUARTERS
- Italy
- OUTSIDE CAPITAL
- No — own capital only
Investment approach
- ROUTES
- Companies (own capital)
Overview
Fidim S.r.l. is the investment vehicle of the Rovati family, which founded the pharmaceutical group Rottapharm and sold it to Meda in 2014; it has interests in biotech, real estate and private equity. In January 2021 it bought over 90% of Copenhagen-listed Athena Investments and in 2020 a stake in the Milan restaurant group Giacomo. It entered Gruppo Barletta (luxury hospitality, Arsenale) in July 2024, and in May 2026 a binding €166M capital increase alongside Global Hotels Real Estate was announced that lifts its stake to up to 23%.
Holdings & investments (3)
- Gruppo BarlettaNOTABLEConsumer & E-commerce · since 2024
- Athena Investmentssince 2021
- Giacomo GroupConsumer & E-commerce · since 2020
Frequently asked questions
Fidim is a single family office based in Italy.
Fidim invests on behalf of the Rovati family (Pharmaceuticals (Rottapharm, sold to Meda in 2014)).
Fidim invests its own capital into companies.
Fidim invests in Biotech & Life Sciences, Real Estate & PropTech and Consumer & E-commerce.
Fidim's holdings and investments include Gruppo Barletta, Athena Investments and Giacomo Group.
The most recent publicly reported investment by Fidim is Gruppo Barletta (€166M capital increase with Global Hotels Real Estate (binding agreement); stake to rise to up to 23%), announced in May 2026.
No. Fidim invests its own capital and does not raise money from outside investors.